Solventum's $125 Million Hangover — and the Handshake That Unlocks 2027
A headline organic decline of 2.8% is really 4% growth, a renegotiated 3M supply deal just deleted a 100bps cliff, and the bear case's favorite subject quietly vanished from the script
SOLV · Earnings Call · 2026-11-05
The quarter that nets out
Solventum's third quarter reads badly on the first line and fine on the second. Reported sales of $1.95 billion fell 7%; organic sales growth was negative 2.8%. But that number carries a $125 million hangover from the second quarter, when the company stuffed distributors ahead of the largest ERP cutover in its history. CFO Wayde McMillan was blunt about the mechanics: “On an organic basis, compared to prior year, sales decreased 2.8%, including the reversal of $125 million ERP-related advanced orders that benefited second quarter results as part of our planned cutover mitigation strategy.” — Wayde McMillan, Chief Financial Officer · 2026-11-05 Strip that out, plus 90bps of deliberate SKU exits, and he put underlying growth at “approximately 4%” — Wayde McMillan, Chief Financial Officer · 2026-11-05 — at the top of a 2026 guide the company then nudged toward the high end.
This is the third straight quarter where the shape of the P&L is dominated by self-inflicted timing noise rather than demand. Volume drove growth, pricing stayed inside the promised plus-or-minus 1%, and the culprit — the ERP program — is now finished. As Bryan Hanson put it, “With the Americas cutover behind us, separation is now more than 90% complete.” — Bryan Hanson, Chief Executive Officer · 2026-11-05 That matters less for the current quarter than for what stops bleeding next year: separation costs roll off starting in Q4 and again in 2027, which is the direct bridge to the free cash flow story management has been promising since the spin.
The handshake that changes 2027
The genuinely new item on this call was not a product or a growth driver. It was a contract. Solventum renegotiated its reverse master supply agreement with 3M, and in doing so removed a live overhang: a contractual step-up in raw material costs scheduled for April 2027 that would have clipped gross margin. This is the freshest high-momentum theme in the company's own keyword set this quarter — supply agreement — and it deserves the prominence.
In exchange for a volume commitment to 3M over a period of time, the amended master supply agreement eliminates the significant step-up in product costs that was scheduled for April 2027. As a result, we no longer anticipate the additional 100 basis points of gross margin headwind that could have begun in Q3 2027.
To see why this is a narrative turn rather than housekeeping, rewind to February. McMillan then described the same clause as an open problem: “we don't have any updates to share at this time, but we are working with 3M to see if there's a better solution for both companies, frankly, than going that road.” — Wayde McMillan, Chief Financial Officer · 2026-02-27 Seven months later, they found one. The consequence is a cleaner 2027 margin bridge, and McMillan quantified it plainly: “if we can achieve next year, just a little bit better than where we're finishing this year, that will be over 120 basis points of expansion because we'll have to overcome that headwind.” — Wayde McMillan, Chief Financial Officer · 2026-11-05 There is a real barrier being cleared here — the 2026 tariff refund gave gross margin a 120bps annual boost that becomes a comp problem next year. The supply deal is what makes the hurdle jumpable.
RemainCo arithmetic — and a conspicuous silence
The other axis is portfolio surgery. Health Information Systems is being separated, with both spin and sale on the table, and the proceeds have a stated hierarchy: protect the investment-grade rating, then return the majority to shareholders. Management has been consistent on the margin math — roughly 400 basis points of annualized net operating margin dilution once stranded-cost offsets and further cost actions are considered. Hanson framed it as a reset with a follow-through: “There's a clear math that takes you down, and then we're going to work on bringing it back up.” — Bryan Hanson, Chief Executive Officer · 2026-11-05 The RemainCo pitch is that four of five growth drivers and Acera stay behind, so their impact gets magnified on a smaller base — and most of the Transform for the Future levers stay too, precisely because HIS margins were already good.
What's more interesting is what management stopped saying. In August, Hanson was expansive on the AI debate in revenue cycle management, calling autonomous coding “a revolution, if you will, inside of revenue cycle management. It is just beginning” — Bryan Hanson, Chief Executive Officer · 2026-08-05; in February he argued “We actually see AI as an opportunity more than we do a threat.” — Bryan Hanson, Chief Executive Officer · 2026-02-27 This quarter, autonomous coding gets a single passing mention and the keyword's momentum in the company's own trajectory has fallen hard. That is not evasion — it's logical. Once HIS is a separate entity, the AI-disruption thesis attaches to a business Solventum won't own. The largest bear argument against the equity is being rehoused with the asset. Investors should note the silence, and note that it's structurally motivated.
Cheap, but not yet clean
Where the numbers land is a company mid-surgery. Trailing revenue of $2.2 billion with a 2% year-over-year lift understates the underlying 4% cadence. Gross margin of 58.2% was up 3.8pp year over year, and the Q3 print of 57.1% beat the internal plan. But the balance sheet still carries net debt of roughly $4.7 billion, which is exactly why the HIS proceeds are earmarked for debt first. Free cash flow is the messiest line: a 4.8% FCF margin looks nothing like the ~$1 billion ex-separation figure management keeps pointing to — and the company maintained its formal $200–300 million reported FCF guide, with the large majority landing in Q4.
At 9.2x trailing net income, the market is paying a distressed multiple for a business that just told you normalized growth is 4%, margins are expanding, and one known 2027 headwind has been removed. The tape agrees modestly: the shares are up 11.3% over 90 days and sit within 5.7% of their September high. The V.A.C. therapy under-penetration argument — 90% of an eligible population not using a therapy with outcome data already in hand — is a genuinely company-unique growth claim, not sector boilerplate, and it survives the HIS split. The tariff refund benefit that flattered 2026, by contrast, is a one-time item the whole market is now lapping; Solventum's edge is that it already banked it and, via the 3M deal, has an answer for the year it disappears.
The bottom line
Nothing here is a demand surprise. The story is an execution milestone — separation essentially done, the riskiest systems work retired, a supply-cost cliff negotiated away — arriving at the moment the company needs a cleaner 2027 to defend its long-range margin target. The tension worth watching is the Q4 exit rate: analysts pressed twice on whether the implied deceleration is conservatism or a real slowdown, and management answered with process, not demand. With HIS leaving and the noise rolling off, next year's comps will finally have nowhere to hide.